This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.


Starting the conversation with your patients

Identifying at-risk patients

50% of men

of men with T2DM may suffer from TD4

Guidelines from the International Society for the Study of the Ageing Male (ISSAM) Hypogonadism panel recommend the investigation of TD in men with the following conditions:2

  • Low libido
  • Poor morning erections
  • Erectile dysfunction
  • Depressed mood
  • Fatigue
  • Decreased vitality
  • Cognitive impairment
  • Insulin resistance
  • Obesity, abdominal obesity
  • Metabolic syndrome
  • Arterial hypertension
  • Type 2 diabetes mellitus (T2DM)
  • Decreased muscle mass and strength
  • Decreased bone mineral density and osteoporosis
  • Use of glucocorticoids, opioids, antipsychotics
52% of men

of men classified
as obese (BMI >30 kg/m2) may suffer from TD4

The British Society for Sexual Medicine (BSSM) guidelines for UK practice suggest screening for TD in men presenting with:3

  • Consistent and multiple signs of TD
  • Erectile dysfunction, loss of spontaneous erections or low sexual desire
  • T2DM, BMI >30 kg/m2 or waist circumference >102 cm (40.2 inches)
  • Long-term use of opiate, antipsychotic or anticonvulsant medication


  1. Khera M, Adaikan G, Buvat J, et al. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(12):1787–1804.
  2. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15.
  3. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. J Sex Med. 2017;14(12):1504–1523.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: